The Rising Popularity of Growth Hormone Therapy and Ensuing Orthopedic Complications in the Pediatric Population: A Review.

Journal and index pages often block iframe embedding. This reader keeps the evidence details in Orthonotes and leaves the source page one click away.

Abstract

Conflict of interest statement: None of the authors have any conflicts of interest to disclose. 15. J Orthop Physician Assist. 2024 Jul-Sep;12(3):e24.00013. doi: 10.2106/jbjs.jopa.24.00013. Diagnosis and Management of Legg-Calvé-Perthes Disease in the Obese Pediatric Population. Beckish L(1), Ging M(1), Mosman M(1), Kelley C(1), Wilkin L(1), Wills O(1), Adams M(1), Pinion C(1), Bilica C(1), Anderson A(1), Sims M(1), Beckish M(2), Schmitt DM(3). Author information: (1)Department of Physician Assistant Studies, West Liberty University, West Liberty, WV, United States of America. (2)Department of Orthopedics, Prisma Health - Upstate, Greenville, SC, United States of America. (3)Department of Biomedical Sciences, West Liberty University, West Liberty, WV, United States of America. Legg-Calvé-Perthes Disease (LCPD) is a condition marked by temporary blood flow disruption to the proximal femur, commonly afflicting children aged 15 and younger. The etiology of the disease is often idiopathic and involves the development of avascular necrosis of the femoral head, subsequently leading to bone weakening and deformity. Obesity exacerbates LCPD, correlating with delayed diagnosis, increased disease severity, and bilateral involvement. Leptin, growth hormone, and other inflammatory mediator alterations in obese individuals contribute to the pathogenesis. Treatment ranges from conservative measures to surgery, with particular challenges in obese patients. An improved understanding of the impact of obesity on LCPD progression is crucial for tailored management and optimal outcomes. DOI: 10.2106/jbjs.jopa.24.00013 PMCID: PMC11698501